Amylyx’s ALS treatment Relyvrio fails PhIII study, biotech to consider withdrawing drug
Relyvrio, Amylyx’s FDA-approved ALS drug, has failed a crucial Phase III trial, the company said on Friday, a major blow to what had been considered one of the few significant options available for the treatment of the deadly neurodegenerative disease. The failure is almost certain to put access to the